Lv3
242 积分 2024-09-06 加入
Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy
4天前
已完结
Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis
5天前
已完结
Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy
6天前
已完结
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis
10天前
已完结
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis
10天前
已完结
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
26天前
已完结
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma
26天前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
26天前
已完结
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia
27天前
已完结
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
27天前
已完结
皖公网安备34019202002308
